GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (NAS:XFOR) » Definitions » PS Ratio

XFOR (X4 Pharmaceuticals) PS Ratio : 111.70 (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is X4 Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, X4 Pharmaceuticals's share price is $0.6702. X4 Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.01. Hence, X4 Pharmaceuticals's PS Ratio for today is 111.70.

The historical rank and industry rank for X4 Pharmaceuticals's PS Ratio or its related term are showing as below:

XFOR' s PS Ratio Range Over the Past 10 Years
Min: 3.87   Med: 13.97   Max: 287.33
Current: 95.59

During the past 9 years, X4 Pharmaceuticals's highest PS Ratio was 287.33. The lowest was 3.87. And the median was 13.97.

XFOR's PS Ratio is ranked worse than
83.84% of 1015 companies
in the Biotechnology industry
Industry Median: 8.69 vs XFOR: 95.59

X4 Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.01.

Back to Basics: PS Ratio


X4 Pharmaceuticals PS Ratio Historical Data

The historical data trend for X4 Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals PS Ratio Chart

X4 Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only - 43.15 - - -

X4 Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 193.33 111.55

Competitive Comparison of X4 Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, X4 Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X4 Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's PS Ratio falls into.



X4 Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

X4 Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.6702/0.006
=111.70

X4 Pharmaceuticals's Share Price of today is $0.6702.
X4 Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


X4 Pharmaceuticals  (NAS:XFOR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


X4 Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


X4 Pharmaceuticals Business Description

Traded in Other Exchanges
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Executives
Paula Ragan director, officer: President and CEO C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139
Mark Baldry officer: Chief Commercial Officer C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arthur Taveras officer: Chief Scientific Officer C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Mary Dibiase officer: Chief Operating Officer 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Adam S. Mostafa officer: See Remarks C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Keith Woods director C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Craecker Francoise De director 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Derek M Meisner officer: General Counsel C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Diego Cadavid officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alison Frances Lawton director 39 ROBINSON ROAD, LEXINGTON MA 02420
Renato Skerlj officer: Chief Scientific Officer C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949